Items Tagged ‘precision medicine’

June 22nd, 2017

Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer

By

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer (TNBC).  Overall patients with TNBC achieved a 71% pathologic complete response to the combination treatment in the […]

View full entry

Tags: Breast Cancer, checkpoint inhibitor, durvalumab, immunotherapy, News, precision medicine, Triple Negative Breast Cancer


June 20th, 2017

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia

By

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more […]

View full entry

Tags: 2016, Acute Myeloid Leukemia, AML, asco, blood cancer, COMFORT 1, Enasidenib, IDH2 gene, jakafi, Leukemia, myelofibrosis, News


June 19th, 2017

FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma

By

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for the treatment of patients with metastatic renal cell carcinoma who have received 2 or more prior lines of therapy.  CB-839 is a first-in-class, oral, selective, potent inhibitor of glutaminase being evaluated in Phase 1/2 clinical […]

View full entry

Tags: afinitor, Calithera Bioscience, CB-839, everolimus, kidney cancer, News, precision medicine, Renal Cancer, renal cell carcinoma


June 12th, 2017

Alecensa Superior to Xalkori in Treatment of Lung Cancer

By

Alecensa (alectinib) halted the spread of lung cancer for a median of 15 months longer than treatment with rival Xalkori (crizotinib) with fewer side effects, according to trial results presented at the 2017 American Society of Clinical Oncology annual meeting in Chicago. Both drugs are designed to treat advanced non-small cell lung cancer (NSCLC) in […]

View full entry

Tags: Alecensa, alectinib, ALK gene, ALK-positive NSCLC, crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, precision medicine, xalkori


June 9th, 2017

FDA Expands use of Zykadia® in First-Line ALK-Positive Non-Small Cell Lung Cancer

By

The US Food and Drug Administration (FDA) approved the expanded use of Zykadia® (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose cancers are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. About Zykadia Zykadia is an oral, selective inhibitor of ALK, a gene that can fuse […]

View full entry

Tags: ALK-Positive Non-Small Cell Lung Cancer, ceritinib, Lung Cancer, News, precision medicine, Zykadia


June 9th, 2017

Shows Improved Outcomes with Addition of Keytruda® in Triple Negative High-Risk Breast Cancer

By

The results from the I-SPY 2 TRIAL investigating Keyytruda (pembrolizumab), in combination with standard therapy as a pre-operative (neoadjuvant) treatment for patients with locally advanced breast cancer were released at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.  The estimated pathologic complete response (pCR) rate increased nearly threefold in patients with triple-negative […]

View full entry

Tags: Breast Cancer, checkpoint inhibitor, keytruda, News, opdivo, PD-1, precision medicine, Triple negative Breast Cancer (TNBC), Yervoy


June 6th, 2017

Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid Cancer

By

Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer. Up to 44 percent of papillary thyroid cancer patients have a B-raf mutation that can be specifically targeted by existing cancer drugs. The […]

View full entry

Tags: B-raf mutations, mekinist, News, papillary thyroid cancer, precision medicine, tafinlar, targeted therapy, Thyroid Cancer


May 30th, 2017

Imfinzi Improves Outcomes for Patients With Stage III Non Small Cell Lung Cancer

By

Positive results for the PACIFIC clinical trial evaluating the novel precision medicine, Imfinzi (durvalumab) as sequential treatment in patients with Stage III non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy have been reported.1 Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, […]

View full entry

Tags: durvalumab, Imfinzi, Lung Cancer - Non-Small Cell, News, nsclc, precision medicine, Stage III non-small cell lung cancer


April 25th, 2017

Recruitment Begins for World’s First Ovarian Cancer Vaccine Trial

By

UConn Health is beginning to recruit patients for the world’s first personalized genomics-driven ovarian cancer vaccine clinical trial. The goal: to prevent an often deadly relapse of the disease in women diagnosed at advanced stages. The pioneering injectable vaccine OncoImmunome works by boosting the patient’s immune response to enable it to destroy ovarian cancer cells […]

View full entry

Tags: clinical trial, immunotherpay, News, Ovarian Cancer, precision medicine, vaccine


April 12th, 2017

Tecentriq Plus Abraxane Results Suggest Novel Immunotherapy PD-1 “Checkpoint” Inhibitors Have Role in Management of Triple-Negative Breast Cancer

By

The investigative agent, Tecentriq (atezolizumb), in addition to the chemotherapy agent, Abraxane (nab-paclitaxel), provides high anti-cancer responses among patients with triple-negative breast cancer. Approximately 10-20% of breast cancers are referred to as triple-negative breast cancer (TNBC). These types of cancers are both hormone-negative and HER2-negative. Hormone-negative breast cancer refers to a type of breast cancer […]

View full entry

Tags: Breast Cancer, News, precision medicine, Tecentriq, tnbc


February 7th, 2017

Imbruvica® is approved by FDA for Marginal Zone Lymphoma

By

The U.S. Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. These data were recently presented at the 58th Annual American Society of Hematology Meeting in December 2016. About Marginal Zone Lymphoma […]

View full entry

Tags: ibrutinib, imbruvica, Marginal zone lymphoma, News, nhl, Non-Hodgkin's Lymphoma, precision medicine


February 6th, 2017

Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer

By

At the 2017 Gastrointestinal Cancers Symposium in San Francisco researchers presented new trial results demonstrating that Opdivo (nivolumab) significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current standard-of-care treatments. About Gastric Cancer Gastric cancer refers to cancer of the […]

View full entry

Tags: Gastric Cancer, immunotherapy, News, nivolumab, opdivo, precision medicine


October 27th, 2016

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

By

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives […]

View full entry

Tags: General Lung Cancer, immune response, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, nsclc, opdivo, PD-1 inhibitors, pembrolizumab, precision medicine